These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3469179)

  • 21. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 24. Respiratory infections: clinical experiences with the new quinolones.
    Davies BI; Maesen FP
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S53-7. PubMed ID: 3438151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis.
    Ahmed B; Bush A; Davies JC
    Arch Dis Child Educ Pract Ed; 2014 Oct; 99(5):181-7. PubMed ID: 24334311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of treatment of bacterial inflammation of the skin with enoxacin].
    Mensing H
    Infection; 1986; 14 Suppl 3():S217-8. PubMed ID: 3531029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma.
    Chodosh S; Tuck J; Pizzuto D
    Scand J Infect Dis Suppl; 1988; 53():22-8. PubMed ID: 3047855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization.
    Petri H; Tronnier H
    Infection; 1986; 14 Suppl 3():S213-6. PubMed ID: 3463546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enoxacin treatment of urinary tract infections in elderly patients.
    Huttunen M; Kunnas K; Saloranta P
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():105-11. PubMed ID: 3162900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enoxacin decreases the clearance of theophylline in man.
    Wijnands WJ; Vree TB; Van Herwaarden CL
    Br J Clin Pharmacol; 1985 Dec; 20(6):583-8. PubMed ID: 3867394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of enoxacin and norfloxacin in patients with cystitis.
    Yamamoto M; Nagai T; Takaba H; Hashimoto J; Miyake K
    Hinyokika Kiyo; 1987 Dec; 33(12):2141-4. PubMed ID: 3482344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
    Covi M; Velluti G
    J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    Dobbs BR; Gazeley LR; Stewart IA; Edwards IR
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():61-6. PubMed ID: 3162903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of quinolones in respiratory tract infections.
    Maesen FP; Davies BI; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enoxacin for the treatment of urinary tract infection.
    Bailey RR; Peddie BA
    N Z Med J; 1985 Apr; 98(777):286-8. PubMed ID: 3857511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
    Baltch AL; Bassey C; Fanciullo G; Smith RP
    J Antimicrob Chemother; 1987 Jan; 19(1):45-8. PubMed ID: 3104277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections.
    Tatsis G; Tsoukalas G; Hatzinikolaou V; Boulbasakos G; Jordanoglou J
    J Int Med Res; 1996; 24(6):478-81. PubMed ID: 8959532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of enoxacin in a patient with cystic fibrosis.
    Miller MG; Ghoneim AT; Littlewood JM
    Lancet; 1985 Mar; 1(8429):646. PubMed ID: 2857989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.